TABLE 1.

Targeted agents for metastatic renal cell cancer (approved): key results of phase III study

ORR, objective response rate; SD, stable disease; PFS, progression-free survival; OS, overall survival; IFN-α, interferon alpha; AVOREN, Avastin and Roferon in Renal Cell Carcinoma; CALBG, Cancer and Leukemia Group B; NA, not available.

^aDCR (disease control rate), CR (complete response)+PR (partial response)+SD (stable disease) ≥3 mo, ^bCB, clinical benefit; OR, objective response (CR+PR), ^cStatistically significant.